Ankit Panthari: Can Haemophilia Serve as A Health System Model for Other Rare Diseases in India?
Ankit Panthari, Former Business Unit Head, Plasma Derived Therapies at Takeda, shared on LinkedIn:
”Had the opportunity to participate in a thought provoking panel discussion at the National Hemophilia Conclave 2026 on an important question: Can haemophilia serve as a health system model for other rare diseases in India?
Haemophilia, despite its continuing challenges and gaps is perhaps one of India’s most evolved examples of how patient advocacy, physician leadership, policy evolution, diagnostics, procurement systems and comprehensive care models can come together to create meaningful progress in rare diseases.
Over the years, Indian haemophilia care has evolved from transfusion based support to plasma derived factors, recombinant therapies, and now non- factor treatments.
Treatment centres have expanded from a few dozen to nearly 400 nationwide.
Diagnosis rates have steadily improved and are now estimated at approximately 18–20%, while prophylaxis adoption is gradually increasing and estimated at around approximately 10%.
What makes the broader rare disease landscape far more challenging is its heterogeneity and complexity.
With more than 10,000 recognized rare diseases globally, conditions differ widely in symptoms, diagnostics, treatment availability, access pathways, and long term outcomes.
Scientifically approved therapies exist for only a minority of diseases.
Even India’s ICMR registry (NRROID), with approximately 16,000 registered patients likely represents only a fraction of the true burden, highlighting the continuing challenges of diagnosis, data capture, registries, and genomic access.
Haemophilia is not a ‘cut copy paste’ model, but a strong operational reference point from which tailored and scalable rare disease ecosystems can evolve.
It was a privilege to exchange perspectives with fellow distinguished panelists and experts from across the rare disease ecosystem.
A special thanks to Dr Naresh Gupta and the Hemophilia Health Collective of North (HHCN) team for curating such a meaningful and forward looking discussion.”
Stay updated with Hemostasis Today.
-
Aug 30, 2026, 17:13J. Meireles-Brandao: Hypertension, Inflammation and Lipoprotein Disease
-
Aug 30, 2026, 17:10Hugh Nguyen: Leading the New Era of Blood Services Across Asia Pacific
-
Aug 30, 2026, 17:09Transforming Childhood Through Access to Hemophilia Treatment – World Federation of Hemophilia
-
Aug 30, 2026, 17:07Raj Bharath: Connecting Clinicians and Researchers to Advance Transfusion Medicine
-
Aug 30, 2026, 17:04Rana Al Hrout: Free FRCPath Haematology Part 1 Exam Preparation Session
-
Aug 30, 2026, 17:02David McGlasson: A 2020 Article Reaches 8,000 Reads
-
Aug 30, 2026, 16:18Tushar Namdeo: Platelets in Different Diseases
-
Aug 30, 2026, 16:16Fatima Zafar: Anaemia – Why This “Common” Condition Should Never Be Ignored
-
Aug 30, 2026, 16:13Umeshkumar C.: Evaluating Scoring Systems and Biomarkers for DIC in Critically Ill Patients